1    For similar levels of urate lowering, the uricosuric agent probenecid had no effect on endothelial

2 erging therapies, including pegloticase, the uricosuric agent RDEA596, and the interleukin-1 inhibito

3 thine oxidase inhibitor, allopurinol, or the uricosuric agent, benziodarone.

4                                              Uricosuric agents are also effective urate-lowering agen

5      This review considers the potential for uricosuric agents from the perspective of recent progres

6                                     Although uricosuric agents provide the most time-honoured approac

7 f diuretics, beta-blockers, allopurinol, and uricosuric agents, self-reported hypertension and gout,

8                       Unlike other available uricosuric agents, the requirement for Cys-32 is unique

9 icaemia is difficult and there is need for a uricosuric diuretic.

10 d hyperuricaemia may lead to the creation of uricosuric diuretics.

11 peline drugs for gout, such as the selective uricosuric drug RDEA594 and various interleukin-1 inhibi

12 -phenylbutyrate and probenecid, the latter a uricosuric drug used clinically to treat gout, markedly

13            Previous studies have suggested a uricosuric effect of vitamin C.

14 tency of 10 drugs in five different classes (uricosuric, nonsteroidal anti-inflammatories, loop diure

15 the impact of xanthine oxidase inhibitors or uricosurics on clinical hypertension and chronic kidney

16 st antihypertensive drugs in possessing mild uricosuric properties and therefore has a role in treati